Materials
- ✓Read 18 slides and the appendix
- ✓Classified: asset company · oral small molecule · HR+/HER2– breast cancer
- ✓Scored the way life science investors read a seed deck
Raise watches investors, financings and the conversations in your field around the clock, and tells you who to approach, why now, and who can introduce you.
Private beta. Some features shown are in development.
Already invited? Sign in
Feedback written for life science decks: evidence, asset vs. platform, and milestones.
Deck feedback built for life science: evidence, asset vs. platform, and milestones.
Ranked against your deck on stage, science, check size and recent deals. Bring your own list too.
Built on each fund’s thesis and recent deals, ready to send from your own email.
A CRM built for the raise: stages, next steps, and one-tap reply logging.
Raise will track podcasts, financings, filings and conferences, and brief you each morning.
It will find paths to investors through your advisors and co-authors, and draft the ask.
It will check each fund’s portfolio for companies that compete with yours.
It will prepare a one-page brief on the partner: recent deals, public remarks, likely questions.
Biotech rounds turn on data readouts, IND timelines and investors who back a modality, not a sector. Generic fundraising tools weren’t built for that. Raise is built by people who have spent years helping life science founders with fundraising, investor strategy, business development and company building, and it’s being shaped with our first beta founders.
We’re building the deepest record of life science investors: the funds, the partners, what they’ve backed and what they’re saying.
Every investor we source is researched, checked against public sources and reviewed by the Bio Founder Raise team.
Stored privately and encrypted. Our team can’t open it without your permission, it’s never used to train AI models, and you can delete it any time.
Firms you add stay in your workspace, and we never add them to our shared database. Our team can’t see your list without your permission.
Raise drafts. It never emails or messages an investor on your behalf.
Pre-seed to Series A: therapeutics, platforms, diagnostics and medtech.